Insilico Medicine provides an AI-driven platform focused on drug discovery and personalized research for Amyotrophic Lateral Sclerosis (ALS). The platform employs deep generative models, reinforcement learning, and other modern machine learning techniques to facilitate novel target identification and the generation of novel molecular structures with desired properties. Founded in 2014, Insilico Medicine has partnered with numerous pharmaceutical and biotech companies, launching multiple R&D pipelines targeting difficult and previously undruggable diseases. The established platform, featuring tools such as PandaOmics, Chemistry42, and InClinico, accelerates the process of drug discovery for ALS by analyzing patient data to identify new therapeutic pathways and potential drug repurposing opportunities, ultimately aiming to enhance personalized medicine for ALS patients.
• reinforcement learning
• ai-driven drug discovery
• deep generative models
• target identification
• drug repurposing
• collaboration with research organizations
• innovative therapies development
• user-friendly interface for data analysis
• Access to basic features of PandaOmics
• Target identification tools
• Basic analytics capabilities
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
No ratings available.
AI platform for drug discovery using advanced data analytics and machine learning.
View DetailsAI-powered platform for drug discovery using novel therapeutics and machine learning.
View DetailsAI-powered small molecule drug discovery platform accelerating drug development.
View DetailsCreate spooky beats online with this unique musical game featuring character-based sound mixing.
View Details